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Endogenous retrotransposition activates oncogenic pathways
in hepatocellular carcinoma. Shukla R, Upton KR, Muñoz-Lopez
M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK,
Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli E, Dos Santos
A, Rapoud D, Guettier C, Samuel D, Natoli G, Carninci P, Ciccar-
elli FD, Garcia-Perez JL, Faivre J, Faulkner GJ. Cell 2013 Mar
28;153(1):101–11. Copyright (2013) Abstract reprinted with
permission from Elsevier.
http://www.ncbi.nlm.nih.gov/pubmed/23540693.
Abstract. LINE-1 (L1) retrotransposons are mobile genetic elements
comprising 17% of the human genome. New L1 insertions can pro-
foundly alter gene function and cause disease, though their signiﬁ-
cance in cancer remains unclear. Here, we applied enhanced
retrotransposon capture sequencing (RC-seq) to 19 hepatocellular
carcinoma (HCC) genomes and elucidated two archetypal L1-medi-
ated mechanisms enabling tumorigenesis. In the ﬁrst example, 4/19
(21.1%) donors presented germline retrotransposition events in the
tumor suppressor mutated in colorectal cancers (MCC). MCC expres-
sion was ablated in each case, enabling oncogenic b-catenin/Wnt sig-
naling. In the second example, suppression of tumorigenicity 18
(ST18) was activated by a tumor-speciﬁc L1 insertion. Experimental
assays conﬁrmed that the L1 interrupted a negative feedback loop by
blocking ST18 repression of its enhancer. ST18 was also frequently
ampliﬁed in HCC nodules from Mdr2(-/-) mice, supporting its assign-
ment as a candidate liver oncogene. These proof-of-principle results
substantiate L1-mediated retrotransposition as an important etio-
logical factor in HCC.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
Transposable elements comprise 44% of the human genome [1].
Three classes of retroelements are active and can contribute to
human disease by acting as mutagens: long interspersed
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elements (SINEs), and 3000 SVAs (SINE-R/VNTR/Alus) [1,2].
The only autonomously active retrotransposons, LINE-1 or L1,
comprise 17% of the human genome with 80–100 copies capa-
ble of retrotransposing themselves, full-length SINEs, and SVAs
[1–3].
Full-length L1s are 6 kb in length with two open reading
frames coding for proteins required for retrotransposition: a ribo-
nucleoprotein p40 (ORF1) and an endonuclease/reverse trans-
criptase (ORF2). Retrotransposition is a ‘copy and paste’
mechanism in which the L1 is transcribed generating an RNA
intermediate, which is concurrently translated to produce ORF1
and ORF2, that is reverse transcribed and inserted back into the
genome creating a new DNA template for further retrotransposi-
tion [1,4,5].
Both the mechanism of retrotransposition itself and the DNA
elements contained within newly integrated L1s, SINEs, or SVAs
have disease causing potential by altering endogenous genes.
During retrotransposition, ORF2 generates two, close proximity
single strand DNA breaks, creating a potential for a double
strand DNA break, chromosomal breaks, deletions, transloca-
tions, and recombination [1,6]. Also, the L1 could insert near
or within a gene, disrupting normal gene expression by altering
transcript splicing or processing due to the L1 poly-A signal
[1,6]. To date, 100 retrotransposon insertion events are linked
to human diseases of which 25 are due to L1 insertional muta-
genesis [6].
Until recently, L1s were thought to be retrotranspositionally
silenced in somatic cells due to L1 promoter hypermethylation,
histone modiﬁcations, and host defence factors like APOBEC3G
expression. However, L1 retrotransposition occurs in germ cells,
the developing early embryo, in neural stem cells and other
somatic human tissues. Moreover, high-throughput sequencing
methods identiﬁed tumor-speciﬁc de novo L1 insertions in lung,
colorectal, ovarian, and prostate cancers [7–9]. These results sug-
gest that retrotransposition is more common than previously
appreciated and may play an important role in the initiation/pro-
gression of human carcinomas.
In the recent issue of Cell, Shukla et al. proﬁled the endoge-
nous retrotransposon landscape in 19 hepatocellular carcinoma
(HCC) tumors and matched adjacent liver tissue positive for
hepatitis B virus or hepatitis C virus utilizing a modiﬁed
Retrotransposon Capture Sequence (RC-seq) methodology. The13 vol. 59 j 616–617
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study rationale was based on 3 ideas: (1) HCC is a carcinoma, (2)
HBV and HCV infection can suppress host defence factors that
suppress retrotransposition, (3) liver inﬂammation precedes
HCC, which could create an environment permissive for retrans-
position via activating cell stress pathways. Their RC-seq analysis
identiﬁed 7689 non-reference genome retrotransposon inser-
tions, of which 7644 insertions were deemed putative germline
insertions containing 160 previously undetected full-length L1
copies. The remaining 45 insertions were pursued as tumor-spe-
ciﬁc insertions: 17 L1, 27 ALU, and 1 SVA. Site-speciﬁc PCR deter-
mined only 12 L1 insertions were tumor-speciﬁc. The RC-seq
methodology proved to be robust, although future whole-gen-
ome sequencing efforts will likely surpass enrichment methods
like RC-seq.
A major strength of this manuscript is that Shukla et al. char-
acterized how both germline and tumor-speciﬁc retrotranspo-
son insertions alter oncogenic pathways in HCC development.
Four patients possessed germline L1 or Alu insertions in the
tumor suppressor gene mutated in colorectal cancers (MCC), a
negative regulator of the oncogenic b-catenin/Wnt pathway in
HCC. These germline retrotranspon insertions (2 L1, 1 Alu)
reduced MCC mRNA and increased b-catenin protein in both
tumor and normal adjacent liver tissue compared to additional
normal liver controls. Interestingly, one HCC molecular subset
is characterized by aberrant activation of b-catenin driven tran-
scription [10]. These data suggest perhaps a predisposition to
HCC with L1 inactivation of MCC. It is unknown how common
germline MCC retrotransposon insertions are and the extent to
which they might increase HCC risk; but these data suggest that
germline MCC alterations could represent a major, inherited risk
factor for HCC.
Twelve tumor-speciﬁc insertions were identiﬁed in which 2
insertions occurred in one patient’s HCC in the suppression of
tumorigenicity 18 (ST18) gene, a zinc-ﬁnger transcription factor.
This insertion increased ST18 transcript and protein by disrupting
an enhancer element likely involved in a negative feedback loop
of ST18 self-regulation. Better evidence is needed to show ST18
expression at high levels can drive HCC development, but this
data strongly motivates such studies.
The study by Shukla et al. highlights the importance of recog-
nizing germline and somatic retrotransposon insertions as aJournal of Hepatology 201source of mutagenesis that can contribute to HCC. At present, it
is not clear if retrotransposon mutagenesis correlates with dis-
ease severity or is a major driver of HCC. However, it is clear that
this source of mutagenesis alters known oncogenic pathways that
could contribute to HCC risk and progression. Fascinating
research areas are clear, including the role of viral infection and
other factors in causing L1 hypomethylation and derepression
of transposition, the stages at which retrotransposon mutagene-
sis plays a role and the effect of inherited variation in L1 activity
in HCC susceptibility.Conﬂict of interest
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